Avid Bioservices Inc (CDMO)

[cjgaddy]

Known Upcoming events, incl. ASCO May30-June1(2 Abstracts)

May21: NYAS: Emerging Approaches to Cancer Immunotherapy, NYC http://tinyurl.com/lfdoksl
…3:10pm: Dr. Rolf Brekken, “Lifting the Veil of Immune Suppression and Inducing Immune Activation through Antibody-mediated Blockade of Phosphatidylserine Signaling”

May29-Jun2: ASCO Annual Meeting 2015, Chicago http://am.asco.org - see: http://tinyurl.com/lfdoksl
...May30 #3060/S.Altiok(Moffitt): “Activation of CD8+ Tumor Infiltrating Lymphocytes by Bavituximab in a 3D ex vivo System of Lung Cancer Patients”
...Jun1 #4109/Adam Yopp(UTSW): “A Phase I/II Study of Bavituximab & Sorafenib in Advanced Hepatocellular (Liver) Carcinoma (HCC)”
Abstracts: https://iplanner.asco.org/am2015/AM2015.aspx (pub. 5-13-15 5pmET)

Jun15: GRC’s “7th Apoptotic Cell Recognition & Clearance Conf.”, Biddeford ME http://www.grc.org/programs.aspx?id=13127
…8:50-9:15pm: Xianming Huang (UTSW), “PS-Targeting Antibodies Overcome Tumor Immunosuppression & Synergize with Immune Checkpoint Blockade"

Jun15-18/Avid/Booth533: BIO Intl. Convention, Philadelphia http://convention.bio.org/2015

~Jul13: FY'15/Q4 (fye 4-30-15) Financials & Conf. Call http://ir.peregrineinc.com/events.cfm

Aug26: CHI’s 10th Annual Immunotherapy & Vaccine Summit (IMVACS), Boston http://tinyurl.com/lfdoksl
… 9-9:30 Jeff T. Hutchins (VP/Preclin-Res.): “Expansion and Activation of T Cells via the Targeting of the Immunosuppressive Ligand PS: Combination Strategy with Conventional, Targeted, and Checkpoint Inhibitor Therapy”

Oct26-29/Avid/Booth909: IBC's BioProcess Intl. Conf. & Exhib, Boston http://www.ibclifesciences.com/BPI

Dec7-10/Avid/Booth307: IBC's Antibody Eng. & Therapeutics, SanDiego http://www.ibclifesciences.com/AntibodyEng